

Published in final edited form as:

*Messenger (Los Angel)*. 2016 June 1; 5(1-2): 92–99. doi:10.1166/msr.2016.1050.

## Carvedilol inhibits cADPR- and IP<sub>3</sub>-induced Ca<sup>2+</sup> release

Anthony J. Morgan<sup>1,\*</sup>, Konstantina Bampali<sup>1,\*</sup>, Margarida Ruas<sup>1</sup>, Cailley Factor<sup>1</sup>, Thomas G. Back<sup>2</sup>, S.R. Wayne Chen<sup>3</sup>, and Antony Galione<sup>1</sup>

<sup>1</sup>Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK

<sup>2</sup>Department of Chemistry, University of Calgary, Calgary, Alberta T2N 1N4, Canada

<sup>3</sup>The Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, T2N 4N1, Canada

### Abstract

Spontaneous Ca<sup>2+</sup> waves, also termed store-overload-induced Ca<sup>2+</sup> release (SOICR), in cardiac cells can trigger ventricular arrhythmias especially in failing hearts. SOICR occurs when RyRs are activated by an increase in sarcoplasmic reticulum (SR) luminal Ca<sup>2+</sup>. Carvedilol is one of the most effective drugs for preventing arrhythmias in patients with heart failure. Furthermore, carvedilol analogues with minimal  $\beta$ -blocking activity also block SOICR showing that SOICR-inhibiting activity is distinct from that for  $\beta$ -block. We show here that carvedilol is a potent inhibitor of cADPR-induced Ca<sup>2+</sup> release in sea urchin egg homogenate. In addition, the carvedilol analog VK-II-86 with minimal  $\beta$ -blocking activity also suppresses cADPR-induced Ca<sup>2+</sup> release. Carvedilol appeared to be a non-competitive antagonist of cADPR and could also suppress Ca<sup>2+</sup> release by caffeine. These results are consistent with cADPR releasing Ca<sup>2+</sup> in sea urchin eggs by sensitizing RyRs to Ca<sup>2+</sup> involving a luminal Ca<sup>2+</sup> activation mechanism. In addition to action on the RyR, we also observed inhibition of inositol 1,4,5-trisphosphate (IP<sub>3</sub>)-induced Ca<sup>2+</sup> release by carvedilol suggesting a common mechanism between these evolutionarily related and conserved Ca<sup>2+</sup> release channels.

### Introduction

Calcium (Ca<sup>2+</sup>) is a highly versatile intracellular signal that regulates a wide range of cellular functions, including exocytosis, contraction, metabolism, transcription, fertilization and cell proliferation<sup>1</sup>. Sources for Ca<sup>2+</sup> signaling include both influx through channels at the plasma membrane and Ca<sup>2+</sup> mobilization from Ca<sup>2+</sup> storage organelles. A key question is how the ubiquitous Ca<sup>2+</sup> signaling ion can control cellular processes with a high degree of specificity. One potential solution is the realization that there are multiple Ca<sup>2+</sup> mobilizing messengers targeting specific Ca<sup>2+</sup> release channels in distinct organelles. Three molecules have satisfied all the criteria for assignment as Ca<sup>2+</sup> mobilizing second messengers. These are IP<sub>3</sub>, and the pyridine nucleotide metabolites, cADPR and NAADP<sup>2</sup>. The first two molecules target Ca<sup>2+</sup> release channels in the cell's largest Ca<sup>2+</sup> storage organelle, the

Tel. +44 1865 271 633, Fax. +44 1865 271 853, antony.galione@pharm.ox.ac.uk.

\*Joint-first authors

endoplasmic reticulum (ER), whilst NAADP releases  $\text{Ca}^{2+}$  from organelles of the endolysosomal system likely through two-pore channels (TPCs) 3, 4.

$\text{IP}_3\text{R}$  and  $\text{RyR}$  channels are the evolutionarily related principal sarco-endoplasmic  $\text{Ca}^{2+}$  release channels mediating  $\text{Ca}^{2+}$  mobilization from this organelle in response to various stimuli 5. These channels are the main mediators of  *$\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release (CICR)* 6, an autocatalytic mechanism by which cytoplasmic  $\text{Ca}^{2+}$  activates the release of  $\text{Ca}^{2+}$  from internal stores. This mechanism contributes to the globalization of intracellular  $\text{Ca}^{2+}$  signals in cells including propagating  $\text{Ca}^{2+}$  waves, since in the absence of such mechanisms buffering mechanisms greatly restrict the spatial diffusion of  $\text{Ca}^{2+}$  signals making them inherently local.  $\text{IP}_3$  and cADPR are thought to evoke openings of channels by sensitizing them to  $\text{Ca}^{2+}$  as a co-agonist 6. Two principal modes for triggering CICR have been proposed. The first is a cytosolic mode whereby an increase in cytosolic  $\text{Ca}^{2+}$  may activate  $\text{Ca}^{2+}$  release channels. The second is a luminal mode whereby an increase in intraluminal  $\text{Ca}^{2+}$  concentrations trigger the opening of  $\text{Ca}^{2+}$  release channels. The latter is associated with the phenomenon of spontaneous  $\text{Ca}^{2+}$  release from ER/SR 7–9, which has been proposed as an important mechanism underlying various cardiac arrhythmias 10.

cADPR was first identified as a  $\text{Ca}^{2+}$  mobilizing molecule in sea urchin eggs and homogenates 11. Previous work had indicated that NAD was enzymatically converted to a  $\text{Ca}^{2+}$  mobilizing agent in sea urchin eggs and homogenates 12. Pharmacological studies showed that cADPR targeted  $\text{RyRs}$  but not  $\text{IP}_3\text{Rs}$  based on cross-desensitization with  $\text{RyR}$  activators and inhibition by  $\text{RyR}$  blockers 13. Furthermore, both divalent cations and the  $\text{RyR}$  pharmacological activator caffeine, potentiate  $\text{Ca}^{2+}$  release by cADPR 14. Subsequent studies in many mammalian cell types support the link between cADPR and  $\text{RyRs}$  and, in cardiac cells, cADPR promotes the production of  $\text{Ca}^{2+}$  sparks and regulates contractility 15 16. An excess of cADPR may be pro-arrhythmic 16, and an inhibitor of the enzyme that synthesizes cADPR is proposed as a novel anti-arrhythmic drug 17. In summary, cADPR is considered a second messenger that acts by sensitizing  $\text{RyRs}$  to CICR 18.

It has long been recognized that spontaneous  $\text{Ca}^{2+}$  release occurs during SR  $\text{Ca}^{2+}$  overload, a process also known as store-overload induced  $\text{Ca}^{2+}$  release (SOICR). This is a luminal mechanism whereby as the ER (or SR) fills with  $\text{Ca}^{2+}$  when the intra-luminal  $\text{Ca}^{2+}$  concentration or amount reaches a certain level or threshold, the opening of  $\text{RyRs}$  is triggered 10. Such mechanisms have been suspected from studies on spontaneous  $\text{Ca}^{2+}$  release from the SR 7–9, but Chen and his colleagues demonstrated a drug that could block the process 19 and also pinpointed the molecular mechanism by which luminal  $\text{Ca}^{2+}$  triggers SOICR 10. Such spontaneous  $\text{Ca}^{2+}$  release may lead to propagating  $\text{Ca}^{2+}$  waves, essential for activation of eggs at fertilization, but potentially fatal in cardiac myocytes since they underlie arrhythmias 20. Chen and his colleagues proposed that, uniquely amongst  $\beta$ -blockers, carvedilol suppresses SOICR itself, in addition to its  $\beta$ -blocking action 19. Luminal amino-acid residues of the  $\text{RyR}$  have been identified as critical for SOICR, and these include the E4872 residue, which is highly conserved not only in  $\text{RyR}$  between species but also in  $\text{IP}_3\text{Rs}$  10. The proposal is that the  $\text{RyR}$  itself acts as a luminal  $\text{Ca}^{2+}$  sensor, rather than an accessory or interacting protein such as calsequestrin, as SOICR can persist in

calsequestrin-null mice 21. The E4872Q mutation in a mouse model suppressed  $\text{Ca}^{2+}$  waves and ventricular tachyarrhythmias (VTs) 10.

It has been shown that, compared to 14 other known  $\beta$ -blockers, carvedilol was the only one effective in inhibiting SOICR 19. This unique inhibitory action of carvedilol on SOICR needs further investigation, as this activity would be contributing to its  $\beta$ -blocking action. Single-channel recordings in lipid bilayers revealed that carvedilol has an impact on the gating properties of RyR2, reducing the duration and increased the frequency of channel openings. In this study, we have utilized the sea urchin egg homogenate preparation 12 which robustly express both IP<sub>3</sub>R and RyR  $\text{Ca}^{2+}$  release mechanisms on microsomal vesicles 22. Furthermore, ER-derived microsomes in sea urchin egg homogenates display spontaneous  $\text{Ca}^{2+}$  release due to  $\text{Ca}^{2+}$  overload, which can be effected by both IP<sub>3</sub>Rs and RyRs 9. This allowed us to examine the effect of carvedilol and analogs on SOICR mediated by the two principal ER-based  $\text{Ca}^{2+}$  release mechanisms. Although the interaction of IP<sub>3</sub> with IP<sub>3</sub>Rs has now been elucidated at the molecular level 23, the mechanism by which cADPR activates RyRs is not well understood, with accessory cADPR binding proteins proposed 24–26. However, since cADPR is known to cause  $\text{Ca}^{2+}$  release by modulating RyRs 13, 14, it allows us to probe the role of SOICR in the mechanism by which cADPR activates RyRs. We find that carvedilol suppresses cADPR-evoked  $\text{Ca}^{2+}$  release, and also attenuates IP<sub>3</sub>-mediated  $\text{Ca}^{2+}$  release. A common mechanism by which carvedilol inhibits a conserved luminal  $\text{Ca}^{2+}$  gate for both  $\text{Ca}^{2+}$  release mechanisms is suggested.

## Materials and Methods

### Sea urchin egg homogenate preparation

Gamete shedding was stimulated by intracoelomic injections of 0.5 M KCl solution and sea urchin eggs from *Lytechinus pictus* were collected. Collection was carried out in artificial sea water (ASW). ASW: 435 mM NaCl, 10 mM KCl, 40 mM MgCl<sub>2</sub>, 15mM MgSO<sub>4</sub>, 11 mM CaCl<sub>2</sub>, 2.5 mM NaHCO<sub>3</sub>, 7 mM Tris base, 13 mM Tris-HCl, pH 8.0. Eggs were de-jellied by passage through 100  $\mu\text{m}$  nylon mesh (Millipore), and then washed 4 times in  $\text{Ca}^{2+}$ -free ASW, with the first two washes containing 1 mM EGTA. Eggs were subsequently washed in intracellular-like medium, glucamine intracellular medium (GluIM). GluIM: 250 mM potassium gluconate, 250 mM N-methyl-D-glucamine, 20 mM Hepes (acid), and 1 mM MgCl<sub>2</sub>, pH 7.2 (pH adjusted with glacial acetic acid). Eggs were homogenized with a glass Dounce tissue homogenizer in ice-cold GluIM supplemented with 2 mM MgATP, 20 U/mL creatine phosphokinase (CPK), 20 mM phosphocreatine (PCr), Complete™ EDTA-free Protease Inhibitor tablets were from Roche. Homogenate (50%, v/v) was then centrifuged at 13,000 x g at 4 °C for 10 s. The supernatant were aliquoted into 0.5 ml portions and stored at -80 °C.

### Fluorimetry to measure $\text{Ca}^{2+}$ release

To measure  $\text{Ca}^{2+}$  changes, egg homogenate was diluted gradually 20-fold over 3 h in GluIM at 17°C supplemented with the ATP regenerating system (to facilitate optimal  $\text{Ca}^{2+}$  loading of the stores), fluorescent dyes were added (Fluo-3, 3  $\mu\text{M}$  final) and fluorescence changes

monitored in a 600  $\mu\text{L}$  aliquot (2.5% v/v) in a stirred micro-cuvette in a Perkin Elmer LS-50B fluorimeter.

Fluo-3 was excited at  $506 \pm 3$  nm and  $526 \pm 2$  nm emission recorded.

The Fluo-3 fluorescence signal was converted to absolute  $\text{Ca}^{2+}$  concentrations by sequential addition of 0.5 mM EGTA and 10 mM  $\text{CaCl}_2$  to determine  $F_{\min}$  and  $F_{\max}$ , using the following equation:

$$[\text{Ca}^{2+}] = [K_d \times (F - F_{\min})] / (F_{\max} - F_{\min})$$

where  $[\text{Ca}^{2+}]$  is the extravesicular  $\text{Ca}^{2+}$  concentration, F is the fluorescence at any time,  $F_{\min}$  and  $F_{\max}$  are the fluorescence in the “absence” of  $\text{Ca}^{2+}$  and presence of saturating  $\text{Ca}^{2+}$ , respectively. At the end of each experiment,  $F_{\min}$  and  $F_{\max}$  were empirically determined by the sequential addition of 500  $\mu\text{M}$  EGTA and 10 mM  $\text{Ca}^{2+}$ , respectively (6  $\mu\text{L}$  of 50 mM EGTA; 6  $\mu\text{L}$  of 1 M  $\text{CaCl}_2$ ).

For TPEN studies of effects on the kinetics of  $\text{Ca}^{2+}$  release, fluorescence (in units (U)/s) was normalized to the resting fluorescence ( $F_0$ ) to account for variability and therefore expressed as  $U.F_0/s$ .

### Source of reagents

cADPR and  $\text{IP}_3$  were purchased from Sigma-Aldrich and LC Laboratories, respectively. Fluo-3 ( $\text{K}^+$  salt) was purchased from Invitrogen and TPEN from Sigma-Aldrich. Carvedilol was purchased from Abcam Biochemicals. VK-II-86, the carvedilol analog, was synthesized as described previously<sup>19</sup>.

### Statistical analysis

Two data sets were compared using Student's t test and multiple groups using ANOVA and Dunnett's multiple comparisons post test. Data were paired when needed and statistical significance assumed at  $P < 0.05$ . Graphs were constructed and the following statistical conventions observed:  $P < 0.05$  (\*),  $P < 0.01$  (\*\*),  $P < 0.001$  (\*\*\*),  $P < 0.0001$  (\*\*\*\*) using Graphpad Prism. Representative fluorimetric traces were plotted as raw fluorescence (RFU) against time.

### Results

To gain further insight into the mechanism of cADPR-induced  $\text{Ca}^{2+}$  release, we examined the effect of carvedilol on  $\text{Ca}^{2+}$  release mechanisms in sea urchin egg homogenates. cADPR-induced  $\text{Ca}^{2+}$  release was monitored in the presence of vehicle DMSO or carvedilol. A sub-maximal concentration of cADPR (0.3  $\mu\text{M}$ ) for  $\text{Ca}^{2+}$  release was determined by establishing a concentration-response curve of cADPR ( $\text{EC}_{50} \sim 0.25$   $\mu\text{M}$ ; Fig. 2b). Preincubation with carvedilol for 2 minutes resulted in a concentration-dependent inhibition of cADPR-induced  $\text{Ca}^{2+}$  release with an approximate  $\text{IC}_{50}$  of 30  $\mu\text{M}$  (Fig. 1b).

Generating a cADPR concentration-response curve in the presence or absence of a sub-maximal concentration of carvedilol revealed that carvedilol reduced the maximal response to cADPR without substantially changing the EC<sub>50</sub> for cADPR (Fig. 2b), i.e. was likely a non-competitive blocker. The EC<sub>50</sub> of cADPR with DMSO (and 95% confidence interval) was 250 nM (153–391 nM) and in the presence of carvedilol it was 410 nM (297–564 nM) (P>0.05).

Next we examined the time course of inhibition by carvedilol. Carvedilol (30 μM) was preincubated with homogenate for 10, 30, 60 and 120 seconds. Our results show that carvedilol suppressed cADPR-induced Ca<sup>2+</sup> release maximally within 10 seconds, and there was no further inhibition at longer incubations (Fig. 3).

In order to investigate whether the effect of carvedilol was unique to cADPR- induced Ca<sup>2+</sup> release and the RyR, we examined the effects of carvedilol on IP<sub>3</sub>-induced Ca<sup>2+</sup> release. The proposed SOICR trigger of RyRs has been proposed to be conserved in IP<sub>3</sub>Rs 10. Carvedilol also suppressed IP<sub>3</sub>-induced Ca<sup>2+</sup> release but the extent of inhibition of IP<sub>3</sub> was less than that for cADPR (Fig. 4).

Caffeine is also a commonly used pharmacological RyR agonist 27. Caffeine has also shown to release Ca<sup>2+</sup> in sea urchin egg homogenates and eggs by activating RyRs 13, 28. We compared the effects of carvedilol on cADPR- and caffeine-induced Ca<sup>2+</sup> release. Different concentrations of carvedilol were preincubated for 2 minutes prior to the addition of 10 mM caffeine 13 or 0.3 μM cADPR (Fig. 5a). Carvedilol suppressed caffeine-induced Ca<sup>2+</sup> release with an IC<sub>50</sub> indistinguishable from to cADPR with IC<sub>50</sub>s of 45 μM (for cADPR) and 51 μM for caffeine. The differences were not statistically significant.

VK-II-86 is a carvedilol analog but with minimal β-blocking activity, demonstrating that the pharmacophore for SOICR inhibition can be separated from that for β-blockade 19, 29. Like Carvedilol, VK-II-86 inhibited cADPR-induced Ca<sup>2+</sup> release in a concentration-dependent manner (IC<sub>50</sub> of 52 μM; Fig. 6b), demonstrating that the β-blocking activity of carvedilol was dispensable for blocking Ca<sup>2+</sup> release in homogenates.

To investigate the proposed luminal mechanism of action of carvedilol, the membrane-permeant low affinity Ca<sup>2+</sup> chelator TPEN (N,N,N',N'- tetrakis(2-pyridylmethyl)ethylenediamine) was employed to allow the manipulation of luminal Ca<sup>2+</sup> as previously shown 30. Different concentrations of TPEN (or ethanol vehicle) were preincubated with homogenates for 2 minutes prior to the addition of 0.3 μM cADPR (Fig. 7a). We found that TPEN inhibited cADPR-induced Ca<sup>2+</sup> release, both in terms of the magnitude and kinetics of response but have a greater impact on kinetics (estimated carvedilol IC<sub>50</sub> of 9 μM and 663 μM for kinetics (Fig. 7c) and magnitude respectively (Fig. 7b). The inhibition by TPEN is consistent with a perturbation of luminal Ca<sup>2+</sup> as previously observed for IP<sub>3</sub> 30. However, the effect of TPEN and carvedilol are dissimilar, as the kinetic data may indicate an additional site of action for carvedilol, and which at high concentrations almost completely inhibits Ca<sup>2+</sup> release in response to cADPR.

## Discussion

In the present study we have demonstrated that carvedilol inhibits cADPR-induced  $\text{Ca}^{2+}$  release in sea urchin egg homogenates. cADPR has been characterized as a second messenger regulating the sensitivity of RyRs to activation by  $\text{Ca}^{2+}$  in sea urchin eggs 13, 14, and widely in plant and animal cells 2. However, the mechanism of action of cADPR, from sea urchin egg to cardiac cells, remains undefined 31. A possible mechanism is for cADPR to activate the RyR indirectly by binding to a protein that is part of the RyR macromolecular complex or to a protein that either translocates itself to the RyR or influences a signalling pathway that regulates RyR activity 26. Another possible mechanism is that cADPR stimulates an increase in the level of SR  $\text{Ca}^{2+}$ , perhaps with the involvement of SERCA 31, resulting in a  $\text{Ca}^{2+}$  overload response. Due to the recent elucidation of the action of carvedilol actions on RyRs, we tested the effect of this drug on cADPR-induced  $\text{Ca}^{2+}$  release in sea urchin egg homogenates. We found that carvedilol was an effective inhibitor of cADPR-induced  $\text{Ca}^{2+}$  release. Carvedilol caused a substantial inhibition (82%) of cADPR-induced  $\text{Ca}^{2+}$  release (Fig. 1). This is unlikely to be due to blocking the cADPR binding site since carvedilol inhibition is likely non-competitive, and carvedilol also inhibits caffeine and also  $\text{IP}_3$ -induced  $\text{Ca}^{2+}$  release. It is known that although cADPR, caffeine and ryanodine can release  $\text{Ca}^{2+}$  by activating RyRs, a selective inhibitor of cADPR, 8-NH<sub>2</sub>-cADPR does not block  $\text{Ca}^{2+}$  release by caffeine or ryanodine implying action at different but interacting sites 32. Therefore we propose also that carvedilol and cADPR act at distinct sites.

VK-II-86 also was found to suppress cADPR-induced  $\text{Ca}^{2+}$  release and this is consistent with the notion that the effect of carvedilol on cADPR-evoked  $\text{Ca}^{2+}$  release is independent of its  $\beta$ -blocking activity.

It has been proposed that carvedilol inhibits spontaneous  $\text{Ca}^{2+}$  release from the SR by a mechanism dependent on a luminal trigger site on RyRs. Amino acid residues important for such triggering have been identified and include a cluster of negatively charged residues at the C-terminal part of the predicted inner helix of the RyR 10. These include the residue E4872 conserved between RyRs, including that for sea urchins (Fig. 8). Importantly, acidic residues at the putative luminal sensor are also conserved in sea urchin  $\text{IP}_3$ Rs. We have shown for the first time that carvedilol also inhibits  $\text{IP}_3$ -induced  $\text{Ca}^{2+}$  release in urchin homogenates (Fig. 4), although to a lesser degree (47% versus >80%) than that for either cADPR or caffeine-induced  $\text{Ca}^{2+}$  release. Since  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  signaling has also been implicated in arrhythmogenesis 33, this may also be pertinent to the clinical effects of carvedilol. Our novel finding that carvedilol can suppress  $\text{IP}_3$ -induced  $\text{Ca}^{2+}$  release also suggests that carvedilol may be a potential therapeutic agent for treating other  $\text{IP}_3$ R-associated disorders in addition 34.

A luminal  $\text{Ca}^{2+}$  regulation site is consistent with the inhibition of a low affinity membrane-permeant  $\text{Ca}^{2+}$  chelator, TPEN. Not only do  $\text{IP}_3$ Rs and RyRs share the conserved acidic residues, but they also share sensitivity to TPEN 30 (and this study). Moreover, since TPEN by modulating luminal  $\text{Ca}^{2+}$  similarly inhibits  $\text{Ca}^{2+}$  release by both  $\text{IP}_3$  and cADPR in a similar way to carvedilol, a common mechanism based on a luminal mechanism is suggested. We previously have proposed that TPEN does not simply reduce the




electrochemical gradient for  $\text{Ca}^{2+}$  because ionomycin-evoked  $\text{Ca}^{2+}$  release is relatively insensitive to TPEN 30. Again, this implies a modulatory role of TPEN on  $\text{Ca}^{2+}$  release channels by lowering luminal  $\text{Ca}^{2+}$ , whereas carvedilol has a similar effect by blocking the luminal  $\text{Ca}^{2+}$  sensor on  $\text{Ca}^{2+}$  release channels.

## References

- Berridge M, Lipp P, Bootman M. The versatility and universality of calcium signalling. *Nature Mol Cell Biol Rev.* 2000; 1:11–21.
- Lee HC. Mechanisms of calcium signaling by cyclic ADP-ribose and NAADP. *Physiol Rev.* 1997; 77:1133–1164. [PubMed: 9354813]
- Calcraft PJ, Ruas M, Pan Z, Cheng X, Arredouani A, Hao X, Tang J, Rietdorf K, Teboul L, Chuang KT, Lin P, et al. NAADP mobilizes calcium from acidic organelles through two-pore channels. *Nature.* 2009; 459:596–600. [PubMed: 19387438]
- Patel S. Function and dysfunction of two-pore channels. *Sci Signal.* 2015; 8:re7. [PubMed: 26152696]
- Seo MD, Velamakanni S, Ishiyama N, Stathopoulos PB, Rossi AM, Khan SA, Dale P, Li C, Ames JB, Ikura M, Taylor CW. Structural and functional conservation of key domains in  $\text{InsP}_3$  and ryanodine receptors. *Nature.* 2012; 483:108–12. [PubMed: 22286060]
- Roderick HL, Berridge MJ, Bootman MD. Calcium-induced calcium release. *Curr Biol.* 2003; 13:R425. [PubMed: 12781146]
- Palade P, Mitchell RD, Fleischer S. Spontaneous calcium release from sarcoplasmic reticulum. General description and effects of calcium. *J Biol Chem.* 1983; 258:8098–107. [PubMed: 6863278]
- Missiaen L, Taylor CW, Berridge MJ. Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. *Nature.* 1991; 352:241–4. [PubMed: 1857419]
- Galione A, McDougall A, Busa WB, Willmott N, Gillot I, Whitaker M. Redundant mechanisms of calcium-induced calcium release underlying calcium waves during fertilization of sea urchin eggs. *Science.* 1993; 261:348–352. [PubMed: 8392748]
- Chen W, Wang R, Chen B, Zhong X, Kong H, Bai Y, Zhou Q, Xie C, Zhang J, Guo A, Tian X, et al. The ryanodine receptor store-sensing gate controls  $\text{Ca}^{2+}$  waves and  $\text{Ca}^{2+}$ -triggered arrhythmias. *Nat Med.* 2014; 20:184–92. [PubMed: 24441828]
- Lee HC, Walseth TF, Bratt GT, Hayes RN, Clapper DL. Structural determination of a cyclic metabolite of NAD with intracellular calcium-mobilizing activity. *J Biol Chem.* 1989; 264:1608–1615. [PubMed: 2912976]
- Clapper DL, Walseth TF, Dargie PJ, Lee HC. Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphosphate. *J Biol Chem.* 1987; 262:9561–9568. [PubMed: 3496336]
- Galione A, Lee HC, Busa WB.  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release in sea urchin egg homogenates: modulation by cyclic ADP-ribose. *Science.* 1991; 253:1143–1146. [PubMed: 1909457]
- Lee HC. Potentiation of calcium- and caffeine-induced calcium release by cyclic ADP-ribose. *J Biol Chem.* 1993; 268:293–299. [PubMed: 8416936]
- Iino S, Cui Y, Galione A, Terrar DA. Actions of cADP-ribose and its antagonists on contraction in guinea pig isolated ventricular myocytes. Influence of temperature. *Circ Res.* 1997; 81:879–84. [PubMed: 9351463]
- Rakovic S, Cui Y, Iino S, Galione A, Ashamu GA, Potter BV, Terrar DA. An antagonist of cADP-ribose inhibits arrhythmogenic oscillations of intracellular  $\text{Ca}^{2+}$  in heart cells. *J Biol Chem.* 1999; 274:17820–7. [PubMed: 10364226]
- Kannt A, Sicka K, Kroll K, Kadereit D, Gogelein H. Selective inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2012; 385:717–27. [PubMed: 22526470]
- Galione A, Cui Y, Empson R, Iino S, Wilson H, Terrar D. Cyclic ADP-ribose and the regulation of calcium-induced calcium release in eggs and cardiac myocytes. *Cell Biochem Biophys.* 1998; 28:19–30. [PubMed: 9386890]


19. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, Tian X, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced  $\text{Ca}^{2+}$  release. *Nat Med*. 2011; 17:1003–9. [PubMed: 21743453]
20. Jaffe LF. Fast calcium waves. *Cell Calcium*. 2010; 48:102–13. [PubMed: 20883893]
21. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Etensohn K, Knollmann BE, Horton KD, Weissman NJ, Holinstat I, Zhang W, et al. *Casq2* deletion causes sarcoplasmic reticulum volume increase, premature  $\text{Ca}^{2+}$  release, and catecholaminergic polymorphic ventricular tachycardia. *J Clin Invest*. 2006; 116:2510–20. [PubMed: 16932808]
22. Morgan AJ, Galione A. Preparation and use of sea urchin egg homogenates. *Methods Mol Biol*. 2014; 1128:161–73. [PubMed: 24567213]
23. Fan G, Baker ML, Wang Z, Baker MR, Sinyagovskiy PA, Chiu W, Ludtke SJ, Serysheva II. Gating machinery of InsP3R channels revealed by electron cryomicroscopy. *Nature*. 2015; 527:336–41. [PubMed: 26458101]
24. Lee HC. Specific binding of cyclic ADP-ribose to calcium-storing microsomes from sea-urchin eggs. *J Biol Chem*. 1991; 266:2276–2281. [PubMed: 1846622]
25. Walseth TF, Aarhus R, Kerr JA, Lee HC. Identification of cyclic ADP-ribose-binding proteins by photoaffinity labeling. *J Biol Chem*. 1993; 268:26686–26691. [PubMed: 8253802]
26. Zhang K, Sun W, Huang L, Zhu K, Pei F, Zhu L, Wang Q, Lu Y, Zhang H, Jin H, Zhang LH, et al. Identifying glyceraldehyde 3-phosphate dehydrogenase as a cyclic adenosine diphosphoribose binding protein by photoaffinity protein-ligand labeling approach. *J Am Chem Soc*. 2017; 139:156–170. [PubMed: 27936653]
27. Meissner G, Lai FA, Anderson K, Xu L, Liu QY, Herrmann-Frank A, Rousseau E, Jones RV, Lee HB. Purification and reconstitution of the ryanodine- and caffeine-sensitive  $\text{Ca}^{2+}$  release channel complex from muscle sarcoplasmic reticulum. *Adv Exp Med Biol*. 1991; 304:241–56. [PubMed: 1666486]
28. McPherson SM, McPherson PS, Mathews L, Campbell KP, Longo FJ. Cortical localization of a calcium release channel in sea urchin eggs. *J Cell Biol*. 1992; 116:1111–21. [PubMed: 1310992]
29. Smith CD, Wang A, Vembaiyan K, Zhang J, Xie C, Zhou Q, Wu G, Chen SR, Back TG. Novel carvedilol analogues that suppress store-overload-induced  $\text{Ca}^{2+}$  release. *J Med Chem*. 2013; 56:8626–55. [PubMed: 24124794]
30. Morgan AJ, Parrington J, Galione A. The luminal  $\text{Ca}^{2+}$  chelator, TPEN, inhibits NAADP-induced  $\text{Ca}^{2+}$  release. *Cell Calcium*. 2012; 52:481–7. [PubMed: 23099186]
31. Venturi E, Pitt S, Galfre E, Sitsapasan R. From eggs to hearts: what is the link between cyclic ADP-ribose and ryanodine receptors? *Cardiovasc Ther*. 2012; 30:109–16. [PubMed: 21176119]
32. Walseth TF, Lee HC. Synthesis and characterization of antagonists of cyclic-ADP-ribose-induced  $\text{Ca}^{2+}$  release. *Biochim Biophys Acta*. 1993; 1178:235–42. [PubMed: 8395888]
33. Roderick HL, Bootman MD. Pacemaking, arrhythmias, inotropy and hypertrophy: the many possible facets of  $\text{IP}_3$  signalling in cardiac myocytes. *J Physiol*. 2007; 581:883–884. [PubMed: 17446217]
34. Hisatsune C, Mikoshiba K.  $\text{IP}_3$  receptor mutations and brain diseases in human and rodents. *J Neurochem*. 2017 in press.






**Fig. 1. Carvedilol suppresses cADPR-induced  $\text{Ca}^{2+}$  release**

(a) Different concentrations of carvedilol or DMSO were preincubated for 2 minutes with a subsequent addition of a sub-maximal concentration of cADPR ( $0.3\mu\text{M}$ ) and the raw control response of cADPR was  $72 \pm 5$  nM ( $n = 9$ ). Summarized representative fluorimetric traces shown in (a) and data fit as a sigmoidal concentration-response shown in (b). Statistical significance was determined with a Dunnett's test in comparison to control response without carvedilol (b). Data are represented as mean  $\pm$  SEM.




**Fig. 2. Carvedilol inhibits cADPR-induced  $\text{Ca}^{2+}$  release**

(a) Summarized representative fluorimetric traces. (b) DMSO or 30  $\mu\text{M}$  of carvedilol were preincubated for 2 minutes before the addition of different cADPR concentrations. Statistical significance was determined using a Student's t test comparing control ( $n = 9$ ) and carvedilol ( $n = 9$ ) (b). Data were fit as a sigmoidal concentration-response (b). Data are represented as mean  $\pm$  SEM.




**Fig. 3. Carvedilol suppresses cADPR-induced  $Ca^{2+}$  release rapidly**

Effect of 30  $\mu M$  carvedilol after preincubation with carvedilol for 10 s, 30 s, 60 s and 100 s is shown. Uncalibrated control  $[Ca^{2+}]$  was  $76 \pm 4$  nM ( $n = 9$ ). Statistical significance was determined using Dunnett's test versus 0  $\mu M$  of carvedilol. Data are represented as mean  $\pm$  SEM.




(a)




(b)

#### Fig. 4. Carvedilol inhibits IP<sub>3</sub>-induced Ca<sup>2+</sup> release

(a) Different concentrations of carvedilol were preincubated for 2 minutes before the addition of sub-maximal concentrations of either IP<sub>3</sub> or cADPR (0.3 μM), which were determined by establishing dose-response curves. Raw control  $[\text{Ca}^{2+}]$  with cADPR was  $72 \pm 4$  nM ( $n = 4-7$ ) and with IP<sub>3</sub>  $94 \pm 1$  nM ( $n = 4-7$ ). (b) Graph summarizing the results. Right Y axis applies for IP<sub>3</sub>, whereas left Y axis for cADPR. Statistical significance was determined using Student's t test and data were fit as a sigmoidal concentration-response. Data are represented as mean  $\pm$  SEM.



(a)




(b)

**Fig. 5. Carvedilol suppresses caffeine-induced Ca<sup>2+</sup> release**


Different concentrations of carvedilol were preincubated for 2 minutes before the addition of sub-maximal concentrations of either caffeine (10 mM) or cADPR (0.3 μM). Raw control

[Ca<sup>2+</sup>] with caffeine was 80 ± 5 nM (*n* = 4–7) and with cADPR 85 ± 3 (*n* = 4–7). Statistical significance (*P* > 0.05) was determined using Student's *t* test and data were fit as a sigmoidal concentration-response. Summarized representative fluorimetric traces are shown in (a).

Data are represented as mean ± SEM.



(a)




(b)


**Fig. 6. VK-II-86 suppresses cADPR-induced Ca<sup>2+</sup> release**

(a) Different concentrations of VK-II-86 or DMSO were preincubated for 2 minutes with a subsequent addition of a sub-maximal concentration of cADPR (0.3 μM) and the raw control response of cADPR was  $75 \pm 4$  nM ( $n = 9$ ). Summarized representative fluorimetric traces shown in (a) and data fit as a sigmoidal concentration-response shown in (b). Statistical significance was determined with a Dunnett's test in comparison to control response without carvedilol (b). Data are represented as mean  $\pm$  SEM.






(a)




(b)



(c)

### Fig. 7. TPEN inhibits cADPR-induced $\text{Ca}^{2+}$ release

- (a) Different concentrations of TPEN (or vehicle ethanol) were preincubated with egg homogenate for 2 minutes prior to the addition of  $0.3 \mu\text{M}$  cADPR.
- (b) TPEN reduces the magnitude of cADPR-evoked  $\text{Ca}^{2+}$  release.
- (c) TPEN affects the kinetics of cADPR-evoked  $\text{Ca}^{2+}$  release. Fluorescence (in units (U)/s) was normalized to the resting fluorescence ( $F_0$ ) to account for variability and therefore expressed as  $\text{U.F}_0/\text{s}$ . Statistical significance was determined using Student's t test and data were fit as a sigmoidal concentration-response. Data are represented as mean  $\pm$ SEM.



**Fig. 8. Key amino acid residues for the proposed luminal Ca<sup>2+</sup> sensor of RyRs and IP<sub>3</sub>R<sub>s</sub> are conserved in sea urchins**

Alignment of amino acid sequences of the pore and inner helix region of RyR2 and IP<sub>3</sub>R2 from human (Hs) and sea urchin (Sp; *Strongylocentrotus purpuratus*). The acidic nature of residue E4872 (in orange) is conserved between RyR2 and IP<sub>3</sub>R2. Sequences (HsRyR2: Q92736; SpRyR2: XP\_011670306; HsITPR2: Q14571; SpITPR2: XP\_011682423) were aligned using Clustal Omega.